IMPROVED INVITRO ANTIGEN-SPECIFIC ANTIBODY-SYNTHESIS IN 2 PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY TAKING AN ORAL CYCLOOXYGENASE AND LIPOXYGENASE INHIBITOR (KETOPROFEN)

In the process of performing a previously published study examining B cell function in 16 patients with common variable immunodeficiency (CVI)(J ALLERGY CLIN IMMUNOL 1991;87:1138-49), we noted improved in vitro antibody (Ab) synthesis in a patient, H.B., while he was taking a cyclooxygenase and lipoxygenase inhibitor, ketoprofen. Addition of ketoprofen in vitro to B cells from patients with CVI resulted in improved proliferation and differentiation in four of five additional patients with CVI studied. One patient, besides H. B., M. K. B., whose B cells secreted increased amounts of antigen (Ag)-specific Ab in response to in vitro ketoprofen, underwent a trial of oral ketoprofen. M. K. B., like H. B., demonstrated improved in vitro Ag-specific Ab production while she was taking oral ketoprofen. No increase in serum Ab levels was noted in either patient taking ketoprofen, but both patients remained infection free during the time of their ketoprofen trials (H. B., 9 months, and M. K. B., 36 months). No improvement in in vitro Ag-specific Ab synthesis was noted when H. B. and M. K. B. took oral cyclooxygenase inhibitors (naproxen or ibuprofen). Thus, additional study is warranted to examine the role of lipoxygenase products of arachidonic acid in the B cell dysfunction of CVI.